Figures & data
Table 1 Patients’ Characteristics
Figure 1 Distribution of teicoplanin trough concentrations. Panel (A) shows the distribution of Cmin on day 3 or day 4 after teicoplanin administration. Panel (B) shows the distribution of teicoplanin Cmin at steady state.
![Figure 1 Distribution of teicoplanin trough concentrations. Panel (A) shows the distribution of Cmin on day 3 or day 4 after teicoplanin administration. Panel (B) shows the distribution of teicoplanin Cmin at steady state.](/cms/asset/bfd8c68e-7a56-455f-bd0f-6af12944e205/didr_a_272982_f0001_b.jpg)
Table 2 Univariate and Multivariate Analyses of the Variables Tested for Potential Association with C3/4min/DCLD
Table 3 Univariate and Multivariate Analyses of the Variables Tested for Potential Association with CSSmin/DMD
Table 4 Univariable and Multivariable Analysis of Risk Factors for Nephrotoxicity in Patients Receiving Teicoplanin